

# GW PHARMACEUTICALS PLC

## **FORM 6-K** (Report of Foreign Issuer)

Filed 12/20/16 for the Period Ending 12/20/16

Telephone	44 1223 266800
CIK	0001351288
Symbol	GWPH
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of December, 2016**

**Commission File Number: 001-35892**

**GW PHARMACEUTICALS PLC**  
(Translation of registrant's name into English)

**Sovereign House  
Vision Park  
Histon  
Cambridge CB24 9BZ  
United Kingdom  
(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes

No

---

## **Notification of Transactions of Directors**

On December 16, 2016, Dr. Stephen Wright, the Chief Medical Officer and a Director of GW Pharmaceuticals plc (the “Company”) exercised options to acquire 281,052 of the Company’s ordinary shares 0.1 pence each (the “Ordinary Shares”). These Ordinary Shares were immediately converted into 23,421 American Depositary Shares (“ADS”) and were sold on the Nasdaq Global Market at the market price of \$116.59 per ADS. Following this sale, Dr. Wright retains a beneficial interest in vested options to acquire 321,938 Ordinary Shares (equivalent to 26,828 ADSs), 4,359 Ordinary Shares (equivalent to 363 ADSs) and unvested options over an additional 449,264 Ordinary Shares (equivalent to 37,439 ADSs). The total number of Ordinary Shares outstanding in the Company is 303,656,708.

For further information, please contact:

GW Pharmaceuticals PLC  
Adam George, Company Secretary

+44 (0)1980 557 000

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**GW Pharmaceuticals plc**

By: /s/ Adam George  
Name: Adam George  
Title: Chief Financial Officer

Date: December 20, 2016

---